卡巴他赛(Cabazitaxel,商品名JEVTANA)作为一种新型的治疗药物,在去势抵抗性前列腺癌(Castration-Resistant Prostate Cancer,CRPC)的治疗中显示出卓越的效果,为患者带来了新的希望。 卡巴他赛由赛诺菲公司开发,并于2010年6月获得了美国食品和药物管理局(FDA)的批准,适用于联合泼尼松治疗先前用含多西紫杉醇的治疗方案治疗...
1.TROPIC试验 TROPIC(Treatment of Refractory Prostate Cancer with Cabazitaxel and Prednisone International Clinical Trial)是一项多中心、随机、开放标签的III期临床试验,旨在评估卡巴他赛联合泼尼松与米托蒽醌联合泼尼松在治疗多西他赛失败后的转移性激素难治性前列腺癌患者中的疗效和安全性。 试验设计:该研究...
Androgen deprivation therapy is initially effective for most patients with metastatic prostate cancer; however, castration-resistant prostate cancer (CRPC) usually develops when disease progresses despite conventional hormone therapies. There are few treatment options for progressive CRPC. Until recently, ...
Paul has been receiving treatment with JEVTANA, after docetaxel, for his advanced prostate cancer. What drives me today is the extra time I’ve gotten to spend with my wife, my children, and my grandchildren. - Paul, Retired Athletic Coach ...
J Drug Target. 2016 Sep 9:1-29. [2]. Gdowski AS, et al. Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain. Nanomedicine (Lond). 2017 Sep;12(17):2083-2095. 规格 10mg 10mM*1mL (in DMSO) 50mg Cabazitaxel 具有显著的抗肿瘤活性。
Cabazitaxel (taxoid XRP6258) is a taxane and antineoplastic agent which is currently used in the therapy of castration-resistant metastatic prostate cancer after failure of docetaxel. 体外活性 使用SF-295和U251人成胶质细胞瘤细胞系,产生原位和皮下鼠异种移植物. Cabazitaxel治疗导致大部分皮下植入的肿瘤完...
Introduction: Although cabazitaxel was proven efficacious by a large Phase III trial and was approved for second-line treatment of metastatic castrate-resistant prostate cancer, case reports describing its efficacy and safety are lacking in the literature. More data is needed describing castrate-...
Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational phase III trial (TROPIC). J Clin Oncol, 28(Suppl; abstr 4508): 15s, 2010...
一:Prednisoneplus cabazitaxel ormitoxantronefor metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Materials :Prednisone MB1327;cabazitaxel MB1403; mitoxantrone MB1478 Methods We undertook an open-label randomised phase 3 trial in men with meta...
清除 Cabazitaxel has a plasma clearance of 48.5 L/h (CV 39%; 26.4 L/h/m2 for a patient with a median BSA of 1.84 m2) in patients with metastatic prostate cancer. 毒理 Cabazitaxel may cause serious side effects including neutropenia, hypersensitivity reactions, gastrointestinal symptoms, and ...